Search Page

1

Cite

Share

Advancing the systemic therapy of lung cancer: quality or quantity?

Fung AS, Leighl NB. Fung AS, et al. Lancet Oncol. 2020 Mar;21(3):322-324. doi: 10.1016/S1470-2045(20)30076-0. Epub 2020 Feb 6. Lancet Oncol. 2020. PMID: 32035512 No abstract available.

Cite

Share

2

Cite

Share

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada.

Elegbede AA, Gibson AJ, Fung AS, Cheung WY, Dean ML, Bebb DG, Pabani A. Elegbede AA, et al. Among authors: fung as. JTO Clin Res Rep. 2021 Oct 28;2(12):100249. doi: 10.1016/j.jtocrr.2021.100249. eCollection 2021 Dec. JTO Clin Res Rep. 2021. PMID: 34877555 Free PMC article.

Cite

Share

3

Cite

Share

Assessment Of Tumour Infiltrating Lymphocytes And Pd-l1 Expression In Adenoid Cystic Carcinoma Of The Salivary Gland.

Chen W, Fung AS, McIntyre JB, Simpson R, Afzal AR, Hao D, Lau H. Chen W, et al. Among authors: fung as. Clin Invest Med. 2021 Mar 21;44(1):E38-41. doi: 10.25011/cim.v44i1.35218. Clin Invest Med. 2021. PMID: 33743575

Cite

Share

4

Cite

Share

A real-world comparison of cisplatin vs cetuximab used concurrently with radiation in the treatment of locally advanced oropharyngeal carcinoma.

Fung AS, Afzal AR, Banerjee R, Debenham B, Hao D. Fung AS, et al. Head Neck. 2021 Jan;43(1):153-163. doi: 10.1002/hed.26469. Epub 2020 Sep 19. Head Neck. 2021. PMID: 32949087

Cite

Share

5

Cite

Share

Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer patients.

Fung AS, Karimi M, Michiels S, Seymour L, Brambilla E, Le-Chevalier T, Soria JC, Kratzke R, Graziano SL, Devarakonda S, Govindan R, Tsao MS, Shepherd FA. Fung AS, et al. Transl Lung Cancer Res. 2021 Feb;10(2):826-838. doi: 10.21037/tlcr-20-927. Transl Lung Cancer Res. 2021. PMID: 33718025 Free PMC article.

Cite

Share

6

Cite

Share

A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.

Kartolo A, Feilotter H, Hopman W, Fung AS, Robinson A. Kartolo A, et al. Among authors: fung as. Cancer Treat Res Commun. 2021;27:100330. doi: 10.1016/j.ctarc.2021.100330. Epub 2021 Feb 6. Cancer Treat Res Commun. 2021. PMID: 33581492 Free article.

Cite

Share

7

Cite

Share

CXCR4 expression in lung carcinogenesis: Evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patients.

Fung AS, Kopciuk K, Dean ML, D'Silva A, Otsuka S, Klimowicz A, Hao D, Morris D, Bebb DG. Fung AS, et al. PLoS One. 2021 Jan 28;16(1):e0241240. doi: 10.1371/journal.pone.0241240. eCollection 2021. PLoS One. 2021. PMID: 33507926 Free PMC article. Clinical Trial.

Cite

Share

8

Cite

Share

Improving the Management of Brain Metastases in Oncogene-Addicted Non-Small-Cell Lung Cancer.

Fung AS, Leighl NB. Fung AS, et al. J Oncol Pract. 2019 Nov;15(11):571-572. doi: 10.1200/JOP.19.00575. J Oncol Pract. 2019. PMID: 31715119 No abstract available.

Cite

Share

9

Cite

Share

Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?

Kartolo A, Robinson A, Fung AS. Kartolo A, et al. Among authors: fung as. Future Oncol. 2022 Feb;18(6):635-638. doi: 10.2217/fon-2021-1348. Epub 2022 Jan 12. Future Oncol. 2022. PMID: 35018801 No abstract available.

Cite

Share

10

Cite

Share

Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.

Kuang S, Fung AS, Perdrizet KA, Chen K, Li JJN, Le LW, Cabanero M, Karsaneh OAA, Tsao MS, Morganstein J, Ranich L, Smith AC, Wei C, Cheung C, Shepherd FA, Liu G, Bradbury P, Pal P, Schwock J, Sacher AG, Law JH, Stockley TL, Leighl NB. Kuang S, et al. Among authors: fung as. Curr Oncol. 2022 Jun 22;29(7):4428-4437. doi: 10.3390/curroncol29070352. Curr Oncol. 2022. PMID: 35877212 Free PMC article.

Cite

Share